Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: Blunt Smoker Denies Tobacco Use, Delaying Diagnosis

Rachel E. Elam, MD, ScM, Vishal Arora, MD, & Alyce M. Oliver, PhD, MD  |  Issue: May 2022  |  May 12, 2022

Brandon Crawford / shutterstock.com

Brandon Crawford / shutterstock.com

Cannabis arteritis mirrors thrombo­angiitis obliterans in its clinical and arteriographic presentation, but its relevant exposure is cannabis rather than tobacco.1 Whether cannabis arteritis is a subset of thromboangiitis obliterans or a unique pathologic entity is debatable.

Delta-9-tetrahydrocannabinol, the primary psychoactive component of cannabis, is a peripheral vasoconstrictor.2 This offers mechanistic insight into how cannabis may cause the distal extremity ischemia characteristic of thromboangiitis obliterans. However, with rare exceptions, at least some tobacco use—concomitant with cannabis use—is reported in cases of cannabis arteritis.3,4

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the U.S., cannabis users infrequently mix loose tobacco with cannabis in a joint (i.e., cannabis rolled in cigarette paper) or pipe, as is typical in other countries.5 Yet almost two-thirds of cannabis users in the U.S. co-administer cannabis and tobacco at least occasionally as a blunt.5

Blunts are cigars or cigarillos that are hollowed out and filled with cannabis. A substantial minority of blunt smokers don’t consider themselves cigar or tobacco users.6 This has significant implications for obtaining the necessary social history in patients with a clinical presentation compatible with cannabis arteritis to reach the appropriate diagnosis, as demonstrated in this case.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Case Presentation

A 61-year-old man presented with a three-day history of diffuse swelling and pain in his right second finger. He had a three-month history of Raynaud’s phenomenon of the digits in both hands and a two-month history of progressively worsening, painful ulcerations of several distal fingertips. He had no inflammatory joint pain or swelling and no extremity numbness. He did not have fevers, weight loss, lymphadenopathy, dyspepsia, rashes or cutaneous nodules. He reported many months of dyspnea on exertion, and non-exertional, non-pleuritic substernal chest pain.

Whether cannabis arteritis is a subset of thromboangiitis obliterans or a unique pathologic entity is debatable.

His past medical history included hypertension and untreated hepatitis C. He had no known personal history of arterial or venous thrombosis. He was not taking any prescription medications, over-the-counter medications or supplements.

He smoked cannabis 8 to 10 times each week. He denied past or current tobacco use. He explicitly, and on multiple occasions, denied past or current smoking of cigarettes, cigars or pipes. He did not use any other drugs. He had no family history of autoimmune or metabolic diseases. He had never worked in an industrial factory.

Physical exam showed digital clubbing, with distal tuft swelling and tenderness of all distal fingertips. Dry ulcerations with a honey-colored crust were present on multiple fingertips, including the right second digit. This finger was diffusely swollen and tender. He could not flex the right second finger at the distal and proximal interphalangeal joints actively or passively due to severe pain. No sclerodactyly was present. The right third toe distal tuft was swollen, with a digital pit.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Conditions Tagged with:cannabiscase reportmarijuanathromboangiitis obliteranstobacco

Related Articles

    Cannabis for Pain Relief: An Area Ripe for Research

    September 28, 2023

    Medical cannabis may benefit patients experiencing pain, and rheumatologists should be able to discuss its potential risks and benefits with their patients. Here are insights from Dr. Mary Ann Fitzcharles on current research, patient use and more.

    Cannabis in Rheumatology Care: A Look at the Latest Research & What Rheumatologists Are Telling Their Patients

    March 26, 2018

    As medical and recreational marijuana becomes more accessible, researchers seek creative ways to study the cannabis plant and explore the complexities of the endocannabinoid system in pain relief. Rheumatologists currently face an influx of patients asking if marijuana can help them. Here’s a look at the evolving research on cannabinoids for rheumatologic pain management and how doctors are discussing it with their patients…

    Cannabinoids Show Potential in Pain Management

    February 13, 2020

    ATLANTA—The potential of cannabis‐based medicines is a hot topic, particularly as pain management therapy for arthritis and other conditions. However, confusion abounds regarding its therapeutic potential, how it can be administered and even the correct terminology to use. David P. Finn, PhD, professor of pharma­cology and therapeutics, and founding co-director of the Centre for Pain…

    Marijuana for Rheumatology Patients?

    February 17, 2018

    SAN DIEGO—What does cannabis offer to the treatment and management of rheumatology patients and the range of pain states they experience? What do we really know about its long-term effects? These are hard questions to answer with currently available data and a reality nuanced by complications cannabis advocates don’t always recognize, according to two experts…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences